Langella, Stephanie http://orcid.org/0000-0001-6082-5491
Barksdale, N. Gil
Vasquez, Daniel http://orcid.org/0000-0002-2586-162X
Aguillon, David http://orcid.org/0000-0003-2283-536X
Chen, Yinghua
Su, Yi http://orcid.org/0000-0002-1946-8063
Acosta-Baena, Natalia http://orcid.org/0000-0002-5319-1619
Acosta-Uribe, Juliana http://orcid.org/0000-0001-9978-093X
Baena, Ana Y.
Garcia-Ospina, Gloria
Giraldo-Chica, Margarita
Tirado, Victoria
Muñoz, Claudia
Ríos-Romenets, Silvia
Guzman-Martínez, Claudia
Oliveira, Gabriel
Yang, Hyun-Sik http://orcid.org/0000-0002-8318-0443
Vila-Castelar, Clara http://orcid.org/0000-0002-8779-1487
Pruzin, Jeremy J.
Ghisays, Valentina http://orcid.org/0000-0002-8434-9407
Arboleda-Velasquez, Joseph F. http://orcid.org/0000-0002-3192-9117
Kosik, Kenneth S. http://orcid.org/0000-0003-3224-5179
Reiman, Eric M. http://orcid.org/0000-0002-0705-3696
Lopera, Francisco http://orcid.org/0000-0003-3986-1484
Quiroz, Yakeel T. http://orcid.org/0000-0001-9714-8244
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01 AG054671)
Article History
Received: 9 February 2023
Accepted: 9 August 2023
First Online: 23 August 2023
Competing interests
: S.L. is supported by a grant from the Alzheimer’s Association (AARF-22-920754). Y.S. reports grants from The Alzheimer’s Association, The BrightFocus Foundation, NIH/NIA, State of Arizona, outside the submitted work. C.V.-C. reports grants from the Alzheimer’s Association (AARF 2019A005859) and the National Institute on Aging (K99AG073452). K.S.K. is on the Board of Directors for the Tau Consortium, receives funding from the NIA, the Alzheimer Association, and the Alzheimer’s Drug Discovery Foundation. H-S.Y. reports a grant from the National Institute of Aging (K23 AG062750). E.M.R. reports grants from National Institute on Aging (P30 AG072980, R01 AG069453, R01 AG055444), Banner Alzheimer’s Foundation and the NOMIS Foundation during the conduct of the study. E.M.R. is a compensated scientific advisor for Alzheon, Aural Analytics, Denali, Retromer Therapeutics, and Vaxxinity, an uncompensated scientific advisor for Lilly, and a cofounder, advisor and shareholder of AlzPATH, which is involved in the development of blood-based biomarkers for Alzheimer’s disease outside the scope of the submitted. In addition, E.M.R. is the inventor of a patent issued to Banner Health, which involves the use of biomarker endpoints in at-risk persons to accelerate the evaluation of Alzheimer’s disease prevention therapies and is outside the submitted work. F.L. was supported by an Anonymous Foundation, and the Administrative Department of Science, Technology and Innovation (Colciencias Colombia;111565741185). E.M.R. and F.L. are principal investigators of the Alzheimer’s Prevention Initiative (API) Autosomal Dominant AD Trial, which is supported by NIA, philanthropy, Genentech, and Roche. Y.T.Q. was supported by grants from the National Institute on Aging (R01 AG054671, RF1AG077627), the Alzheimer’s Association, and Massachusetts General Hospital ECOR. Y.T.Q. serves as consultant for Biogen. The remaining authors declare no competing interests.